

To discuss with the duty biochemist call 0114 243 4343

References: (1) Clin Endocrinol. 2011;75:743-746. (2) DTB 2013;51:33-36.
(3) <u>www.acb.org.uk/Nat%20Lab%20Med%20Hbk/Magnesium.pdf</u>
(4) <u>https://www.nice.org.uk/advice/esuom4/chapter/key-points-from-the-evidence</u> (accessed 08/09/15)

Oral Magnesium Preparations. Magnaspartate[®] is the only preparation licensed as a medicinal product and therefore should be used first line in the oral replacement of magnesium deficiency. In individual cases where Magnaspartate[®] is deemed not suitable e.g. due to the sucrose content or other reasons, a prescriber may feel it in the patient's best interest to prescribe an unlicensed preparation such as Magnaphate[®]

Magnesium (Mg ²⁺) salt and form	Supplier (Brand)	Licensed status in UK	Form and strength of salt (where available)	Mg ²⁺ content in dosage form	
				mg	Mmol
Magnesium-L- aspartate	KoRa Healthcare Ltd (Magnaspartate [®])	Prescription only medicine	6.5g oral powder	243	10
	Contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Care should also be taken in diabetic patients. Frequent and long-term use of Magnaspartate 243 mg may be harmful to the teeth (caries). If an undesirable effect occurs, such as diarrhoea, the therapy should be temporarily interrupted and can be restarted after improvement and /or elimination of the symptoms with a reduced dosage. For more information see http://www.medicines.org.uk/emc/medicine/30238				
Magnesium glycerophosphate	Arjun Products Ltd (Magnaphate [®])	Borderline substance	1g tablets	97.2	4

Table adapted from <u>http://www.ukmi.nhs.uk/</u> Medicines Q&A: **Magnesium preparations for hypomagnesaemia** [LINK] (accessed 12/08/2015). For more information please refer to this document.